Safety of Anlotinib Capsules Combined with PD-1 Inhibitor Camrelizumab in the Third-Line Treatment of Advanced Non-Small-Cell Lung Cancer and Their Effect on Serum Tumor Markers.

Yinhua Wang,Bin Ye,Zhaoling Zou,Qinghua Qi,Xiuhua Shi,Kalidoss Rajakani

doi:10.1155/2021/2338800

Abstract

Objective To explore the safety of anlotinib capsules combined with the PD-1 inhibitor (camrelizumab) in the third-line treatment of advanced non-small-cell lung cancer (NSCLC) and their effect on serum tumor markers. Methods 88 patients with advanced NSCLC treated in the Oncology Department of our hospital from December 2018 to December 2019 were selected as research subjects and randomly and equally split into the single treatment group (STG) and combined treatment group (CTG). The levels of serum tumor markers after treatment were detected in both groups, and the incidence of adverse reactions during treatment was recorded. Results Compared with the STG, CTG achieved obviously higher total effective rate (P < 0.05), lower total incidence of adverse reactions (P < 0.05), lower levels of serum tumor markers and average CFS score (P < 0.001), and higher average KPS score (P < 0.001). Conclusion Application of anlotinib capsules combined with the PD-1 inhibitor (camrelizumab) in the third-line treatment of advanced NSCLC can effectively reduce the levels of serum tumor markers and cancer fatigue degree of patients, with a better effect than that of simple anlotinib treatment. In addition, further research of the combined treatment is helpful to establish a better therapeutic regimen for patients with advanced NSCLC.

Highlights

With the changes in people’s lifestyle and environment, the incidence of lung cancer in China has increased [1]
Non-small-cell lung cancer (NSCLC) has a high incidence, accounting for about 65–80% of lung cancer, and the chemotherapy drugs are mostly cytotoxic drugs, which can fight against cancer and reduce tumors by damaging the DNA structure and affecting nucleic acid synthesis, but can trigger adverse reactions such as gastrointestinal reactions and myelosuppression because they do not have specificity for tumor cells and have a lethal effect on normal cells [5,6,7]. ird-line treatment refers to the treatment adopted after the failure of the second-line treatment
Camrelizumab, a humanized monoclonal antibody extracted from the hamster ovary cell line by recombinant technique, can bind to programmed death receptor-1 (PD-1), block the binding of PD-1 and programmed death receptor ligand 1 (PD-L1), reactivate T cells, produce sustained antitumor effect, and inhibit tumor growth, which has been confirmed in primary liver cancer with lung metastasis [11]

Summary

Objective

To explore the safety of anlotinib capsules combined with the PD-1 inhibitor (camrelizumab) in the third-line treatment of advanced non-small-cell lung cancer (NSCLC) and their effect on serum tumor markers. E levels of serum tumor markers after treatment were detected in both groups, and the incidence of adverse reactions during treatment was recorded. Compared with the STG, CTG achieved obviously higher total effective rate (P < 0.05), lower total incidence of adverse reactions (P < 0.05), lower levels of serum tumor markers and average CFS score (P < 0.001), and higher average KPS score (P < 0.001). Application of anlotinib capsules combined with the PD-1 inhibitor (camrelizumab) in the thirdline treatment of advanced NSCLC can effectively reduce the levels of serum tumor markers and cancer fatigue degree of patients, with a better effect than that of simple anlotinib treatment.

Introduction

Materials and Methods

Inclusion and Exclusion Criteria

Results